Skip to main content

Barwon Health / Research

(03) 4215 0000

Cancer Services Trials Unit

Cancer Services at Barwon Health has a long and distinguished history conducting clinical research through a dedicated clinical trials unit established in 1997 at the Andrew Love Cancer Centre – the Cancer Services Trials Unit (previously known as the Haematology and Oncology Trials Team (HOTT)). 

The unit conducts cooperative, investigator-initiated and sponsored phase 1b-III/IV studies across a wide range of haematological malignancies and solid tumours. Trials are selected by investigators according to scientific and ethical merit as well as clinical need, enabling local patients to access novel therapies in the first-line treatment setting or beyond second-line when patients are less likely to have readily available and accessible standard of care treatment options.

Our clinical trial portfolio has grown significantly in recent years and our aim is to provide patients with increasing access to clinical trials in line with the state government’s Victorian Cancer Plan. The CSTU is currently involved in 63 active trials featuring 550 patients, with 30 more now open for recruitment and 13 to commence soon. These trials span a range of cancer types including lymphoma, leukaemia, myeloma, breast, melanoma, lung, prostate, and urology.

Our research activity benefits our regional patients, minimising their requirement to travel to larger metropolitan centres to access the latest novel therapies.

Keen to find out more about clinical trials at Barwon Health?

Click here to watch CSTU trials in cancer and chemotherapy: Dr Chiara Bortolasci, Clinical Trials Manager, Cancer Services Trials Unit (CSTU), Barwon Health (5 min)

Research Areas

Collaborating Organisations

Victorian Comprehensive Cancer Centre (VCCC)

Cancer Council Victoria (CCV)  Cancer Trials Australia (CTA) National Health and Medical Research Council (NHMRC) Australasian Leukaemia & Lymphoma Group (ALLG)

Australian Lung Cancer Trials Group (ALTG)

Breast Cancer Trials (BCT) ANZ Gynaecological Oncology Group (ANZGOG) ANZ Urogenital and Prostate Cancer Trials Group (ANZUP) Clinical Oncology Society of Australia (COSA)

Medical Oncology Group of Australia (MOGA)

The Trans Tasman Radiation Oncology Group (TROG) Australasian Gastro-Intestinal Trials Group (AGITG) Monash University School of Public Health and Preventive Medicine  


Research Team

Research Staff


Haematology Investigators

Medical Oncology Investigators

  • Dr David Campbell MBBS FRACP, Head of Medical Oncology, 
  • Dr Patricia Banks, MB BS Bsc(Hons) FRACP
  • Dr Anna Lomax, MBBS BSc FRACP
  • Dr Caitlin Murphy, MB BS(Hons) BA FRACP
  • Dr Inger Olesen, MBBS (Hons) FRACPn
  • Dr Madhu Singh, MBBS FRACP
  • Dr Karen White, MBBS FRACP
  • Dr Shu Fen Wong, BMedSci MBBS FRACO Master of Applied Science

Radiation Oncology Investigators

  • Dr Michael Francis, MBBS FRANZCR
  • Dr Andrew Hui, MBBS FRANZCR Mmed (clin epi)

Haematology & Oncology Trials Team

Research Students

SKILLED Interns:

  • Justin Dennis

Research News

Research Grants

  • Commonwealth of Australia (Commonwealth) as represented by the Department of Health (DH) - ReViTALISE Project: Bridging the metro-regional trials gap by 2025: 2021-2026
  • Victorian Cancer Agency (VCA) - Improving Rural Health Outcomes through the Regional Trials Network-Victoria: 2021-2023

Featured Publications

Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry. Nguyen J, Wellard C, Chung E, Cheah CY, Dickinson M, Doo NW, Keane C, Talaulikar D, Berkahn L, Morgan S, Hamad N, Cochrane T, Johnston AM, Forsyth C, Opat S, Barraclough A, Mutsando H, Ratnasingam S, Giri P, Wood EM, McQuilten ZK, Hawkes EA; Lymphoma and Related Diseases Registry investigators. Eur J Haematol. 2023 Apr;110(4):386-395. doi: 10.1111/ejh.13915. Epub 2022 Dec 28. PMID: 36539351

Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. Ghia P, Pluta A, Wach M, Lysak D, Šimkovič M, Kriachok I, Illés Á, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery EJ, Lee JH, Usenko G, Wang MH, Yu T, Jurczak W. Hemasphere. 2022 Nov 14;6(12):e801. doi: 10.1097/HS9.0000000000000801. eCollection 2022 Dec. PMID: 36398134
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg CN, Watkins SP, Despain D, Simmons AD, Loehr A, Dowson M, Golsorkhi T, Chowdhury S; TRITON2 investigators. J Clin Oncol. 2020 Nov 10;38(32):3763-3772. doi: 10.1200/JCO.20.01035. Epub 2020 Aug 14. PMID: 32795228
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, Voog EG, Bryce AH, McDermott R, Ricci F, Rowe J, Zhang J, Piulats JM, Fizazi K, Merseburger AS, Higano CS, Krieger LE, Ryan CJ, Feng FY, Simmons AD, Loehr A, Despain D, Dowson M, Green F, Watkins SP, Golsorkhi T, Chowdhury S. Clin Cancer Res. 2020 Jun 1;26(11):2487-2496. doi: 10.1158/1078-0432.CCR-20-0394. Epub 2020 Feb 21. PMID: 32086346
Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Cochrane T, Campbell BA, Gangatharan SA, Latimer M, Khor R, Christie DRH, Gilbertson M, Ratnasingam S, Palfreyman E, Lee HP, Trotman J, Hertzberg M, Dickinson M. Intern Med J. 2021 Dec;51(12):2119-2128. doi: 10.1111/imj.15503. Epub 2021 Nov 22. PMID: 34505342

Support Our Research

Participate in a Clinical Trial

To find out about Clinical Trials currently underway at Barwon Health, click here.


Clinical trials require ongoing investment and there are several ways to support this amazing work.

You can make a donation today and contribute to an item on our research wish list, consider a bequest in your will, or establish a lasting legacy fund in your name. No matter what size, your philanthropic support with deliver an immediate impact.

To donate now or for more information and further discuss your support, please contact the Barwon Health Foundation.


Last Modified: Tuesday, 06 February 2024

Research Leads


A/Professor Philip Campbell
Director of Cancer Services and Head of Haematology


Dr David Campbell
Head of Medical Oncology

 chiara bortolasci 005 smaller

Dr Chiara Bortolasci
Clinical Trials Manager 


Andrew Love Cancer Centre
70 Swanston Street
Geelong VIC 3220

Ph (03) 4215 2758
Fax (03) 4215 2835

[email protected]

[email protected]